NCT02133014

Brief Summary

The purpose of this study is to analyze the effect of laparoscopic-assisted percutaneous catheter drainage of early SAP(severe acute pancreatitis).We are going to select 60 cases SAP patients from April 2014 to April 2015 who carry on the treatment in our hospital,and divide into the experimental group and control group under respect the wishes of patient in the case.The experimental group use the method of laparoscopic-assisted percutaneous drainage to carry on the treatment,the control group patients use conventional conservative therapy to carry on the treatment.Contrastive analyze two groups of patients clinical care effects. Research hypothesis:according to compare the mortality,the incidence of complications ,hospital stay and other research indicators of two groups .It is supposed that the research indicators of experimental group are lower than the control group ,difference was statistically significant(P\<0.05).We can draw the conclusion that the method of laparoscopic-assisted percutaneous catheter drainage of early SAP is useful and deserve to be promoted on clinical.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

April 28, 2014

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 7, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

May 7, 2014

Status Verified

April 1, 2014

Enrollment Period

1 year

First QC Date

April 28, 2014

Last Update Submit

May 3, 2014

Conditions

Keywords

pancreatitislaparoscopicdrainagesurgery

Outcome Measures

Primary Outcomes (1)

  • mortality

    one year

Secondary Outcomes (1)

  • the incidence of local Complications

    within the first 30 days (plus or minus 3 days) after surgery

Other Outcomes (1)

  • hospital stay

    participants will be followed for the duration of hospital stay, an expected average of 4 weeks

Study Arms (2)

surgical operation therapy

EXPERIMENTAL

Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.

Procedure: laparoscopic-assisted percutaneous catheter drainageDrug: 0.5% 5-fluorouracil normal saline

conventional therapy

NO INTERVENTION

using the method of conventional conservative therapy without surgical management.

Interventions

Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline

Also known as: surgical therapy
surgical operation therapy

On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.

Also known as: 5-FU, f5U
surgical operation therapy

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • organ dysfunction(one organ or multiple organs)
  • local complications(pancreatic necrosis;pancreatic abscess;pancreatic pseudocyst);Ronson score of ≥3;
  • APACHE-Ⅱscore of ≥8;
  • Balthazar CT grade D or grade E.

You may not qualify if:

  • mild acute pancreatitis;
  • chronic acute pancreatitis;
  • on admission has received surgical treatment;
  • pregnant and lactating women ;combined with heart,lung,liver,kidney severe primary disease;psychopath;
  • malignant tumor
  • immunocompromised state.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Hepatobiliary Surgery(I),Zhujiang Hospital

Guangzhou, Guangdong, 510280, China

RECRUITING

Related Publications (1)

  • Echenique AM, Sleeman D, Yrizarry J, Scagnelli T, Guerra JJ Jr, Casillas VJ, Huson H, Russell E. Percutaneous catheter-directed debridement of infected pancreatic necrosis: results in 20 patients. J Vasc Interv Radiol. 1998 Jul-Aug;9(4):565-71. doi: 10.1016/s1051-0443(98)70323-9.

MeSH Terms

Conditions

Pancreatitis, Acute NecrotizingPancreatitis

Interventions

Fluorouracil

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

UracilPyrimidinonesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Fan y fang, Prof.

    Department of Hepatobiliary Surgery(I),Zhujiang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wang li qing, doctor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2014

First Posted

May 7, 2014

Study Start

April 1, 2014

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

May 7, 2014

Record last verified: 2014-04

Locations